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Cellular immune responses, particularly those associated with CD3+CD8+ cytotoxic T lymphocytes (CTL), are critical factors 
in controlling viral infection. Nasopharyngeal carcinoma (NPC) is closely associated with persistent Epstein-Barr virus (EBV) 
infection. NPC vaccine studies have focused on enhancing specific antiviral CTL responses. In this study, three vaccines capa-
ble of expressing the EBV-latent membrane protein 2 (LMP2) (a DNA vector, an adeno-associated virus (AAV) vector, and a 
replication-defective adenovirus serotype 5 (Ad5) vector) were respectively used to immunize female Balb/c mice (4–6 weeks 
old) at weeks 0, 2 and 4, either alone or in combination. Our results suggest that combined immunization with DNA, AAV, 
and adenovirus vector vaccines induced specific cellular immunity more effectively than any of these vectors alone or a com-
bination of two of the three, constituting a sound vaccine strategy for the prevention and treatment of NPC. 
EBV-LMP2, DNA vaccine, recombinant adenovirus vaccine, recombinant adeno-associated virus vaccine, combinato-
rial immunization, specific cell-mediated immune responses 
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Epstein-Barr virus (EBV) is associated with a number of 
human malignancies. One of the most widely spread EBV-    
associated malignancies, nasopharyngeal carcinoma (NPC), 
has a high incidence rate of 10–50 cases per 100000 people 
per year in the southern regions of China [1–3]. Although 
the tumor is responsive to radiotherapy and a combined 
treatment of radiotherapy and chemotherapy, it is resistant 
to these therapies in about 30% of patients [3]. Therefore, it 
is necessary to develop novel treatments for NPC. EBV 
existing in the tumor tissue provides an ideal target for cy-
totoxic T lymphocyte (CTL)-based immunotherapy, and 
therefore immunotherapy may become a beneficial com-
plementary approach to the conventional treatments of NPC. 
EBV infection in NPC cells exhibits a latency II pattern and 
the viral proteins EBNA1, LMP1 and LMP2 are expressed. 
LMP2 mRNAs are regularly detected in NPC tumor cells. 
Although the LMP2 protein has not been reproducibly de-
tected with currently available techniques, antibodies to 
LMP2 are frequently detected in sera obtained from NPC 
patients [4]. Meanwhile, among all EBV proteins, LMP2 is 
most readily recognized by CTLs. Additionally, many 
HLAI restricted epitopes of LMP2 that are conserved across 
different populations have been identified [5−8]. Therefore, 
LMP2 is an ideal target for NPC immunotherapy. 
MHC class I-restricted CTLs are a key factor in control-
ling the status of EBV infection. EBV-specific CTLs are 
present at high levels in the blood during the initial stages of 
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infection and persist for the entire period of the viral infec-
tion. When the level of CTL responses is reduced, as seen in 
patients receiving organ transplantation or in HIV-infected 
individuals, EBV-induced lymphocyte proliferation will 
occur. However, when immunosuppression is alleviated or 
autologous EBV-specific CTLs expanded in vitro are in-
fused back to the patients, the cellular immune responses 
will recover, and the disease will regress [9]. These obser-
vations suggest that the EBV-specific immune responses 
might be useful in the treatment of EBV-associated human 
tumors. To develop a therapeutic vaccine for NPC, Zuo 
JianMin et al. [10] from our laboratory constructed rAd-    
LMP2, a recombinant adenovirus containing the full-length 
cDNA of EBV-LMP2. The adenoviral vector has a broad 
host-range, its transduction efficiencies for cells in both 
quiescent and dividing phases are high, and it can express 
high levels of target protein in a short time [11]. In vivo 
animal studies of AIDS vaccines showed that priming with 
a viral vector or DNA vaccine followed by boosting with 
another vector induced stronger immune responses in com-
parison to vaccination with a single vaccine [12]. Therefore, 
two additional types of vaccine, a DNA vaccine and an 
adeno-associated virus (AAV) vaccine were also included 
in our experiments. Injection of a DNA vaccine into an 
animal can directly transfect animal cells with the DNA and 
the antigenic proteins expressed can induce CTL responses 
to a greater degree [13]. Recently, AAV has been proposed 
as a promising vehicle for gene therapy due to its broad host 
range, excellent safety profile, and stable expression of 
genes in the host system. A major advantage of AAV is that 
in comparison to other viral vectors, they exhibit an ex-
tremely low immunogenicity [14]. The aim of this study 
was to investigate the immunologic effects of combined 
immunization with DNA, AAV and adenoviral vaccines of 
EBV-LMP2, in comparison to individual immunization 
with each vaccine. 
1  Materials and methods 
1.1  Vaccine vectors 
1.1.1  DNA vaccine 
The vector pVR-LMP2 was constructed by inserting the 
EBV-LMP2 gene into the VR plasmid under the control of 
the human cytomegalovirus (CMV) intron A promoter and 
bovine growth hormone terminator. Plasmid pVR-LMP2 
was dissolved in phosphate-buffered saline (PBS) at a con-
centration of 1 mg mL−1. 
1.1.2  AAV vaccine 
The same EBV-LMP2 gene was used in the construction of 
the AAV-1 vector. AAV-1 is a pseudotyped AAV vector 
containing ITRs and the Rep gene from AAV-2, and the 
Cap protein from AAV-1. The EBV-LMP2 gene was cloned 
into pSNAV-1, an expression plasmid of recombinant AAV, 
to construct the recombinant plasmid pSNAV-LMP2. BHK 
cells were transfected with pSNAV-LMP2 to establish BHK- 
LMP2, an LMP2-expressing stable cell line; BHK-LMP2 
cells were infected with HSV1-rc/ΔUL2, and the recombi-
nant virus, rAAV2/1-LMP2, was generated and purified.  
1.1.3  Adenovirus vector vaccine 
The rAd-LMP2, a recombinant replication defective adeno-
virus type 5 containing the full-length cDNA of EBV-LMP2 
was constructed in our laboratory. 
1.2  Immunization 
Female Balb/c mice (4–6 weeks old) were purchased from 
the Institute of Laboratory Animal Sciences (Chinese 
Academy of Medical Sciences). Seven groups of five mice 
were immunized by intramuscular injection at week 0, and 
boosted twice at weeks 2 and 4. The immunization program 
is shown in Table 1. All mice remained healthy throughout 
the experiments. The immunization doses of PBS, pVR-    
LMP2, rAd-LMP2 and rAAV2/1-LMP2 used were 100 μL, 
100 μg, 5×1010 and 1×1011 viral particles (vp), respectively.  
1.3  ELISPOT assay 
The level of LMP2-specific IFN-γ-secreting cells in mice 
was determined using an ELISPOT assay kit (BD™ 
ELISPOT Mouse IFN-γ ELISPOT set; BD Biosciences) 
following the manufacturer’s protocol. Mouse spleen lym-
phocytes (5×105) were stimulated with an EBV-LMP2 pep-
tide pool (4 μg mL−1 final concentration) and incubated at 
37°C/5% CO2 for 24 h. Untreated cells were used as the 
background control. Cells were removed after 24 h and  
200 μL deionized water was added to each well. Subse-
quently, the plate was washed with PBS containing 0.05% 
(v/v) Tween 20 (PBS-T) and incubated with pre-diluted 
biotinylated anti-IFN-γ antibody assay solution (100 μL/well) 
for 2 h at room temperature. The antibody solution was dis-
carded and the plate was washed three times with PBS-T. A 
100 μL volume of a streptavidin-horseradish peroxidase con-
jugated anti-biotin antibody was added to each well and the 
plate was incubated for 1 h at room temperature. The  








1 PBS PBS PBS 
2 pVR-LMP2 pVR-LMP2 pVR-LMP2 
3 pVR-LMP2 pVR-LMP2 rAd-LMP2 
4 pVR-LMP2 rAd-LMP2 rAd-LMP2 
5 rAd-LMP2 rAd-LMP2 rAd-LMP2 
6 rAAV2/1-LMP2 rAAV2/1-LMP2 rAAV2/1-LMP2 
7 rAAV2/1-LMP2 pVR-LMP2 rAd-LMP2 
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plate was washed four times with PBS-T, twice with PBS, 
and then 100 μL of AEC color development solution was 
added to each well. The plate was incubated in the dark at 
room temperature. When clear spot formation was observed, 
deionized water was added to the wells and the reactions 
were terminated with two washes. After the plate was 
air-dried at room temperature, the spots were counted in a 
computer-assisted video image analyzer. The results were 
expressed as the number of spot-forming cells (SFC) per 
million cells. 
1.4  Adenovirus-specific neutralizing antibody assay 
Mouse sera taken from Groups 1, 3, 4 and 5 mice at week 5 
post-immunization (diluted 1:50) were incubated with an 
equal volume of serially diluted Ad5 vector (1010, 109, 108, 
107, 106, 105, 104 and 103 viral particles) at 37°C for 1 h. 
The mixture was incubated with Hek 293 cells in a 96-well 
plate at 37°C for an additional 96 h. The cytopathic effect 
was analyzed after 96 h incubation. The neutralizing titer 
was expressed as the number of neutralized Ad5 particles at 
a 1:50 dilution. 
1.5  Data analysis 
All results were expressed as mean±SD. Statistical analyses 
of the experimental data and control were conducted by 
one-way factorial analysis of variance (ANOVA), with sta-
tistical significance defined as P<0.05. 
2  Results 
2.1  Specific cellular immunity 
Seven groups of five mice were respectively immunized in-
tramuscularly with pVR-LMP2, rAAV2/1-LMP2, Ad-LMP2, 
or a combination of these vaccines, at weeks 0, 2 and 4 ac-
cording to the program shown in Table 1. The levels of 
EBV-LMP2-specific T cells were determined by Elispot 
assay as described in Materials and methods. The mean 
values obtained for the groups are listed in Table 2. 
One-way factorial analysis of variance showed that the val-
ues for Groups 3 (pVR-LMP2, pVR-LMP2, rAd-LMP2), 4  
Table 2  Cellular immune responses induced in different groups of mice 
Group No. Mean SFC STD N 
1 22.4000 5.54977 5 
2 49.6000 26.43483 5 
3 927.2000 164.00976 5 
4 770.0000 100.55844 5 
5 368.8000 149.36265 5 
6 109.2000 68.53612 5 
7 1023.2000 122.60995 5 
(pVR-LMP2, rAd-LMP2, rAd-LMP2), 5 (rAd-LMP2, rAd-     
LMP2, rAd-LMP2), and 7 (rAAV2/1-LMP2, pVR-LMP2, 
rAd-LMP2) were significantly higher than that of Group 1 
(PBS control; P<0.01 for all) and the values for Groups 3, 4 
and 7 were significantly higher than that of Group 5 (P< 
0.01; Figure 1). 
These results indicate that the magnitude of vaccine-    
induced T-cell responses was related to the immunization 
strategies. Individually, rAd-LMP2 (Group 5) induced 
higher specific cellular immune response than pVR-LMP2 
(Group 2) and rAAV2/1-LMP2 (Group 6). However, the 
highest response was induced when the mice were immu-
nized with all three vaccines (Group 7). The second highest 
response was induced by priming with pVR-LMP2 twice 
followed by boosting with rAd-LMP2 (Group 3) whereas 
priming with pVR-LMP2 once and boosting with rAd-LMP2 
twice was not as effective.  
2.2  Adenovirus-specific neutralizing antibody assay 
Titers of anti-adenovirus neutralizing antibodies in the sera 
of Groups 1, 3, 4 and 5 mice were assayed. The neutraliza-
tion titers were expressed as the number of Ad5 particles 
neutralized at a 1:50 dilution of the serum sample. Repeated 
administration of Ad-LMP2 induced an increase in the titer of 
anti-adenovirus neutralizing antibodies (Table 3).  
 
 
Figure 1  IFN-γ-ELISPOT histogram of spleen lymphocytes from mice 
treated with various vaccine strategies (1×106 spleen lymphocytes). a, 
significantly higher than Group 1 (P<0.05); aa, much higher than Group 1 
(P<0.01); bb, much higher than Group 2 (P<0.01); cc, much higher than  
Group 5 (P<0.01). 











1 − 1×106 1×108 1×109 
2 − 1×105 1×108 1×109 
3 − 1×106 1×108 1×109 
4 − 1×105 1×108 1×109 
5 − 1×105 1×108 1×109 
Mean − (6.40±4.93)×105 (1.00±0.00)×108* (1.00±0.00)×109* 
a) *, the value was significantly higher than that of Group 3 (P<0.05). 
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3  Discussion 
There is increasing interest in the use of viral and non-viral 
systems as vectors to elicit anti-EBV-LMP2 immune re-
sponses for the treatment of certain tumors. Comparative 
studies on the immunogenicity of the vectors and entire 
systems in non-human primates have provided experimental 
evidence for the clinical application of these vectors. It has 
been found in animal experiments that priming with a viral 
vector or nucleic acid vaccine followed by boosting with 
either another vector or a subunit/polypeptide vaccine in-
duced stronger immune responses compared with vaccina-
tion with either vaccine alone [12,15]. Over the past decade, 
several prime-boost strategies have been tested for an HIV 
vaccine and the results have been promising [16,17]. 
In this work, we evaluated the cellular immune responses 
to EBV-LMP2 induced by DNA, AAV and adenovirus 
vectors. Our results showed that the combined immuniza-
tion with DNA, AAV, and adenovirus vectors was promis-
ing in inducing specific anti-LMP2 CTL responses. A com-
bination of DNA and adenovirus vectors also elicited robust 
LMP2-specific CTL responses in mice. The DNA vectors 
had very low immunogenicity. We also found that immuni-
zation with the AAV vector alone elicited low cellular im-
mune responses. Because similar observation has been re-
ported previously [18], we did not further pursue the immu-
nization strategy with AAV alone in this study. Our study 
focused on LMP2-specific CTL responses elicited by the 
strategy of AAV-DNA-rAd5 immunization. 
Based on common adenovirus serotypes, the immuno-
genicity of a vaccine may be reduced by any pre-existing 
immunity against the viral vector. The results of the present 
study showed that the levels of EBV-LMP2-specific T cells 
tended to decrease with increasing time of immunization 
with the adenovirus type 5 vector. Increased doses and 
times of administration will increase the titer of neutralizing 
antibodies, and will subsequently reduce the efficiency of 
gene delivery [19]. 
All these results strongly suggest that the synergy ob-
served in the three vaccines present a feasible strategy for 
circumventing the negative effects of generally existing 
high adenovirus type 5 immunity in human populations. 
In conclusion, our results suggest a good prospect for the 
application of combined immunization with DNA, AAV, 
and adenovirus vectors in producing cellular immunity in 
human. Based on our study, Rhesus monkey trials have 
been designed. These trials will assess the tolerability and 
immunogenicity of DNA, AAV, and adenovirus type 5 
vectors expressing the LMP2 protein, either alone or in 
combination. 
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